Macleods Pharma recalls products in US on account of manufacturing issues

According to the US health regulator, the New Jersey-based Macleods Pharma USA is recalling the affected lot due to "eCGMP (current good manufacturing practices) deviations".;

Published On 2022-03-14 06:39 GMT | Update On 2022-03-14 06:39 GMT

New Delhi: Macleods Pharmaceuticals is recalling two products in the US market due to deviation from standard manufacturing norms, according to a USFDA report. According to the latest enforcement report issued by the US Food and Drug Administration (USFDA), the US-based arm of the drug firm is recalling 3,672 bottles of Amlodipine and Olmesartan Medoxomil tablets, used to treat high blood pressure.

According to the US health regulator, the New Jersey-based Macleods Pharma USA is recalling the affected lot due to "eCGMP (current good manufacturing practices) deviations".

The lot has been manufactured by the Mumbai-based Macleods Pharmaceuticals at its Baddi (Himachal Pradesh) based production plant.

The company initiated the nationwide Class II recall on February 15 this year.

Macleods is also recalling a lot of Olanzapine tablets, used to treat schizophrenia, in the US market. The USFDA noted that the company is recalling the affected lot also for eCGMP deviations.

The company had produced the affected lot at its Baddi plant and later marketed in the US market by Macleods Pharma USA Inc.

The company initiated the Class II voluntary recall on February 16, 2022.

As per the USFDA, a Class II recall is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.

According to industry estimates, the US generic drug market was estimated to be around USD 115.2 billion in 2019.

Established in 1989, Macleods Pharmaceuticals has eight manufacturing units in India. It produces a wide range of formulations in multiple dosage forms, including oral solids (tablets and capsules including soft gelatin capsules), oral liquids, dry syrups, topicals, granules, inhalers and aerosols, and injectables.

The company has a presence across various countries including the US, the UK and Spain.

Read Also - Macleods Pharma to raise 5000 crore via IPO

Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

MD Bureau

Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Macleods Pharma recalls products in US on account of manufacturing issues

According to the US health regulator, the New Jersey-based Macleods Pharma USA is recalling the affected lot due to "eCGMP (current good manufacturing practices) deviations".;

Similar News

CDSCO Criminal Prosecution Against IndiaMART Put on Hold by Delhi HC Till Sept 17

Novo Nordisk Gets CDSCO Panel Nod for Rybelsus Label Update, Aligned with EMA

NPPA Updates Ceiling Price Applicability for Ringer Lactate Non-Glass Packs, Details

CDSCO Eases Rules for Biopharma Research, Will Accept Lab Biosafety Committee Approvals

41 Pharmacies in Delhi Caught Illegally Selling Abortion Pills Mifepristone, Misoprostol

Visakhapatnam Pharma Plant Gas Leak Claims Chemist's Life, CITU Alleges Negligence

Torrent Pharma to acquire 26% stake in Torrent Urja 27 for captive renewable power project

Sanofi Tzield approved in China for adult, pediatric patients with stage 2 type 1 diabetes